|
EQS Newswire / 09/10/2026 / 14:11 UTC+8 Today, after a patient completes a chest CT scan, clinicians pull up the images, review prior test results and treatment histories, and interpret what the new findings signify. Tomorrow, the next wave of trillion-dollar medical AI companies will likely emerge from three pillars: clinician workflow systems used day-to-day, datasets spanning the entire patient care journey, and foundational models that continuously deliver new diagnostic capabilities. Tracing this trajectory reveals three global hubs. Pro Medicus (ASX: PME) in Melbourne, Australia, built its business around imaging workflows; Tempus AI (NASDAQ: TEM) in Chicago, US, focuses on diagnostics and patient data; Diagens Tech (HKEX: 2526) in Hangzhou, China, innovates with medical imaging foundational models. As of 8 October 2026, their respective market capitalisations stood at approximately RMB 78 billion, RMB 84 billion, and RMB 22 billion. Each company began with a distinct business focus: Pro Medicus primarily sells imaging software; Tempus generates most of its revenue from molecular diagnostics and data services; Diagens Tech deploys medical imaging large foundational models into hospitals and clinical practice. Together, they illuminate a critical industry question: if workflows and data already command high valuations, could models that continuously generate clinical capabilities become the third high-value asset class in medical AI? This article argues that Diagens Tech is positioning itself to occupy exactly this niche. By expanding from one regulated use case to additional specialties and hospital sites, it empowers clinical specialists to build, deploy and operate thousands of custom models on one unified foundation. As AI infinitely amplifies specialist expertise, medical imaging foundational models evolve from standalone technology products into scalable platform assets.
A Paradigm Shift: Health Demands Answers, and Above All, Evidence The arrival of large models in healthcare reshapes how people engage with health information. In 2026, OpenAI rolled out health features that connect to medical records and Apple Health with user consent, reporting that more than 300 million people submit health queries to ChatGPT each week. Health management may shift from sporadic web searches to continuous insight, reminders and follow-up queries. Even so, while large language models can interpret reports, they cannot validate tumour shrinkage or organ damage from that data alone, let alone deliver reliable forecasts of disease progression. On another frontier, AI is transforming drug discovery. Google DeepMind’s AlphaGenome examines how genetic variants alter molecular properties; NVIDIA and Eli Lilly announced up to USD 1 billion joint investment over five years; Rentosertib, a candidate drug co-developed by Insilico Medicine, entered Phase Ⅲ trials in 2026. From molecular hypotheses to clinical trials, models now contribute to discovery and R&D decisions. Health management seeks to understand what occurs within the body, while drug development explores how treatments alter disease outcomes. Both rely on reproducible, observable clinical evidence. As the primary source of clinical evidence, medical imaging covers roughly 14,000 indication-specific tasks across CT, MR, ultrasound, endoscopy, pathology, microscopy, dermatoscopy and fundus imaging, accounting for 80% of all global clinical data. According to the World Health Organization, over 25 billion medical imaging scans are performed worldwide each year. This massive volume makes imaging one of the richest, most reliable observation layers within healthcare systems. Medical records, comparatively, are human-language documentation of those core observations. Model development and clinical trials are converging in medical imaging. Google’s MedGemma 1.5 delivers interpretation for 3D CT, MRI and pathology images, while Microsoft’s CARE‑X focuses on chest X-ray reading and lesion localisation. The Swedish MASAI randomised trial enrolled approximately 106,000 women. Within a defined breast screening pathway, the AI-assisted workflow achieved higher breast cancer detection sensitivity (80.5% versus 73.8%), with comparable false positive control (98.5% specificity in both arms). Advances in technical performance and clinical evidence are converging. The next question defining industry value centres on integrating these capabilities into clinicians’ daily tools and building sustainable revenue streams.
Pro Medicus’ Screens in Melbourne: Imaging Information Management Software — Embedded in Clinicians’ Daily Workflows The “screens” referenced here refer to end‑to‑end workflow management software for clinicians to view, compare and analyse medical images. Pro Medicus’s Visage7 integrates image viewing, archiving and workflow management. Clinicians open, review and compare imaging data on this system every day. Going forward, once hospitals organise image reading, reporting and cross‑institutional collaboration around this platform, the software may become central to clinical operations. This pathway has delivered tangible commercial outcomes. In fiscal2026, Pro Medicus recorded approximately AUD261.7million in revenue and AUD127.5million in operating cash inflow, with disclosed minimum contracted revenue of around AUD1.3billion over the next five years. The market assigns it a valuation well above its current‑period revenue. Long‑term contracts, workflow‑embedded products and proven cash‑generating capacity underpin this valuation. Melbourne demonstrates the first key insight: in high-frequency, trust-reliant healthcare settings, the daily access portal used by clinicians is itself a valuable asset. Yet smooth image visualisation only addresses operational needs. To interpret what imaging findings mean for an individual patient, clinicians also require the patient’s diagnostic, examination and treatment context.
Tempus’ Data in Chicago: Connecting Single Tests to a Patient’s Lifelong Care Journey Tempus offers a second benchmark. Its core revenue comes from molecular diagnostics – understanding disease via genetic and molecular information – linking test results, clinical records, data applications and pharmaceutical R&D needs. Its implications for the industry are that value can extend beyond diagnosis when textual data connects a patient’s long‑term disease trajectory, treatment decisions and real‑world outcomes. In Q2 2026, Tempus generated USD382.5million in revenue, including USD289.3million from diagnostics and USD93.2million from data and applications. Tempus also disclosed delivery of the first version of its oncology foundational model to AstraZeneca. Tempus’s valuation reflects data generated by its diagnostic business, capabilities for deploying data to clinicians and pharmaceutical companies, and its sustained revenue growth.
Diagens Tech’s Foundational Model in Hangzhou: Turning Clinicians from Users into Creators The promising future of medical AI emerges from a recent in-depth conversation between Dr. Ning Song, Founder and Chairman of the Board of Diagens Tech and Kevin Kelly, founding editor-in-chief of WIRED, the renowned global technology publication. Dr. Song drew an analogy between print shops and office productivity software. Document creation once required outsourced typesetting and printing, a slow and costly process. After document-editing tools became accessible on personal computers alongside printers, the volume of documents people could create exploded. Yet global healthcare still operates differently: vendors select disease areas, build AI tools independently and hand finished products to hospitals. Spending RMB 300 million over three years to build one disease-specific imaging AI tool remains common. Dr. Song envisioned a comparable shift: radiologists can leverage state-of-the-art imaging foundational models to train custom diagnostic AI rapidly, accurately and affordably for their own specialties. He described this future medtech ecosystem as “a flourishing bloom of custom clinical AI solutions”. While endorsing this innovative framework, Kevin Kelly noted that for a world-leading medical AI company, the journey to realise this vision forms its strongest competitive moat. Medical imaging foundational models operate on a simple principle: learn general anatomy and lesion characteristics from vast libraries of CT, ultrasound and pathology scans, then adapt to targeted clinical assessments using specialty-specific patient cases. The shared foundation absorbs the heavy upfront investment, allowing new use cases to reuse existing capabilities. Diagens Tech discloses its iMedImage® foundational medical imaging model spans 19 imaging modalities and 26 clinical specialties. For certain low-data scenarios, a specialty model can be trained within two to three months using roughly 200 imaging samples. Its iMedMaaS® model training and deployment platform enables clinicians to run no-code training and on-premise deployment using in-hospital datasets. Hospitals thereby shift from purchasing off-the-shelf algorithms to defining clinical challenges and co-building tools. For this production system to work, image volume is only the starting point; clinical expertise must be integrated into datasets. Diagens Tech reports that iMedImage® was trained on more than 80 million medical images. Its iMedLoop™ medical imaging AI R&D and production acceleration platform hosts 28.95 million annotated records, built with contributions from over 3,000 specialised professionals. A “record” refers to one sample entry, which may contain multiple images – much as a single CT scan generates sequential slices. Raw scans expose the model to diverse anatomical variations, while expert annotations identify lesion locations and classification rules. Annotation, quality control and evaluation transform raw image data into usable clinical knowledge for model training. Hospitals can also train models locally using their own data. As of mid-2026, Diagens Tech had partnered with 99 hospitals to deliver 158 model projects. New clinical challenges defined by hospitals, paired with annotation and evaluation frameworks co-developed by specialists, form building blocks for future applications. Notably, the number of models Diagens Tech trains within a single year exceeds the total volume of medical imaging AI models developed across China in the past decade. Translating this production capacity into clinical adoption requires market-ready products and paying customers. AI AutoVision®, built on iMedImage®, is software designed to help clinicians analyse karyograms and detect abnormalities. It obtained Class III medical device registration from China’s NMPA in May 2026. In its clinical trial, the “clinician+AI” workflow delivered readings in an average of 11.3 minutes, compared with 34.1 minutes for conventional workflows. In the first half of that year, Diagens Tech generated RMB 94.541 million in model service revenue via model and technology licensing, cloud services and on-premise deployment, marking year-on-year growth of 101.1%. The registered product demonstrates how foundational models translate into clinical use, while model service revenue confirms customers are paying for model generation and delivery capacity. The vision of “flourishing bloom” therefore gains commercial substance: clinicians define new clinical challenges, and the platform continuously delivers specialty capabilities using a unified toolset.
The Trillion-Dollar Question: From an Imaging-AI Factory to Disease-Interpretation Infrastructure What challenges does this “factory” need to tackle? Medical imaging diagnostics cover 14,000 indication-specific tasks. This count refers neither to hardware nor individual images, but to distinct examinations designed for separate clinical objectives. Even for chest CT, lung cancer screening, pulmonary embolism detection and pneumonia assessment represent separate indications, requiring different imaging protocols and clinician interpretation workflows. Each task demands specialised capabilities; medical imaging forms a vast, fragmented landscape of clinical requirements. Scale brings its own constraint: many clinical conditions lack sufficient patient samples. A study published in Nature Communications identified 5,568 imaging-linked diseases and anomalies across more than 40,000 patient cases, many represented by fewer than 30 samples. The traditional “one model for one disease” paradigm requires fresh case collection, expert annotation, training and validation for every new task. Costs and timelines compound when addressing tens of thousands of niche use cases. Cross-task reusable foundational models embed shared imaging comprehension within a single foundation, allowing clinicians to adapt models using specialty-specific samples. This makes it feasible to cover these long-tail clinical needs at a manageable cost. The true expansion enabled by foundational models lies in the total volume of clinical capabilities that can be built. This factory unlocks another capability: supporting researchers to frame new questions about disease progression. Imaging captures physical changes within the body. When linked to pathology, genetics, treatment records and patient outcomes, models can probe: which early markers signal recurrence? Which patients will respond best to a given therapy? This is AI for Science in medical imaging: identifying correlations from large-scale clinical observations and generating testable medical hypotheses. Research published in Nature Cancer has sought to infer tumour gene expression from pathology slides to predict therapeutic response. Diagens Tech’s research advances along this same path. Its iMedImage® technical report reveals the team combined contrast-enhanced CT, clinical and pathological data to predict one-year post-surgical recurrence risk for pancreatic cancer, achieving an AUC of 0.78 across 89 external test samples. An AUC value closer to 1 denotes stronger ability to stratify patients by risk. A separate study combines cervical ultrasound and maternal clinical histories to forecast preterm birth risk. Model research is shifting its focus from “what can be observed today” to “how disease may evolve over time”. In September 2026, Diagens Tech established a joint laboratory with the Hong Kong Polytechnic University to investigate medical imaging analysis, healthcare foundational models and research workflow automation. The logical thread spanning these three cities now forms a complete loop. Pro Medicus owns the daily software access portal for clinicians; Tempus integrates textual findings into AI-powered long-term patient journey databases for diagnostics and pharmaceutical R&D; Diagens Tech builds a production platform empowering clinicians worldwide to build new models. Its growth follows two clear vectors: expanding into more hospitals, and addressing numerous specialty AI diagnostic needs within each site. Shared foundational models cut development costs for new tasks. Extending beyond diagnosis into prognosis, patient stratification and treatment response research opens opportunities to serve academic institutions and life science companies. This reveals a new dawn for human health management, as the field shifts from Cure Medicine toward Care Medicine. Amid the promising outlook for human well-being, the three cities, three pathways and three sets of valuations remain underappreciated. Diagens Tech’s growth journey represents humanity’s quest to manage health more effectively and precisely. Melbourne shapes clinicians’ daily workflows, Chicago maps patients’ lifelong care journeys, and Hangzhou establishes a new benchmark for human health. At the frontiers of AI, we welcome a new era of human well‑being.
09/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News. Media archive at www.todayir.com |
Category Archives: EQS Newsfeed
Cantourage and Green Karat deepen strategic partnership following EU-GMP certification
|
Cantourage Group SE / Key word(s): Product Launch/Miscellaneous Cantourage and Green Karat deepen strategic partnership following EU-GMP certification 09.10.2026 / 08:14 CET/CEST The issuer is solely responsible for the content of this announcement.
Cantourage Group SE (ISIN: DE000A3DSV01) is strengthening its position as a leading European platform for medical cannabis. Its long-standing Canadian partner Green Karat obtained EU-GMP certification effective 1 October 2026. Cantourage supported the certification process as sponsor and certification partner and is Green Karat’s exclusive distribution partner for products manufactured by Green Karat in the European Union and the United Kingdom. The certification marks an important step in Cantourage’s strategy of helping leading international cannabis producers access the European market while securing attractive products and brands for its core European markets through exclusive partnerships. The partnership between Cantourage and Green Karat is built on a long-standing relationship of trust. EU-GMP certification takes the collaboration to the next level: Cantourage will be able to import finished products manufactured by Green Karat directly from Canada in accordance with EU-GMP standards. This can help make products available to pharmacies across Europe sooner after harvest. “Cantourage has been an important and trusted partner for us in Europe for many years. The company combines deep regulatory expertise with strong access to the European markets that matter to us and a clear understanding of high-quality cannabis products. Working with Cantourage on the EU-GMP certification process was therefore a natural next step. The certification creates the basis for bringing our products to patients in Europe more directly and quickly, and for continuing to grow our presence across Europe together,” said Jen-Frederick Nadeau, founder and CEO of Green Karat. “Green Karat has been a trusted partner for many years, and this certification marks an important next step in our collaboration. By supporting our partners through EU-GMP certification, we are building a more flexible and resilient supply chain and strengthening access to high-quality products for patients and customers across Europe,” said Philip Schetter, CEO of Cantourage Group SE. At the same time, the model offers Cantourage tangible strategic and operational benefits. Shifting production steps to EU-GMP-certified cultivation partners gives Cantourage greater flexibility across its value chain and opens up additional manufacturing capacity. A broader production footprint also reduces operational concentration risk and strengthens supply-chain resilience. This positions Cantourage to expand its business with premium products from international partners efficiently and at scale. Green Karat is one example of Cantourage’s broader certification strategy. Cantourage is already working with other leading international producers on certification processes, which are expected to be completed by the end of 2026. The company is continuing to strengthen its role as a certification partner and as a gateway to the European market for Canadian and other international cannabis producers. For Cantourage, the combination of exclusive partnerships, regulatory expertise and an international network of high-quality producers is a key pillar of its European growth strategy. The company intends to further develop its role as a link between leading international cannabis producers and European markets. About Cantourage Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards. The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).
09.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Cantourage Group SE |
| Feurigstraße 54 | |
| 10827 Berlin | |
| Germany | |
| E-mail: | info@cantourage.com |
| Internet: | https://www.cantourage.com/ |
| ISIN: | DE000A3DSV01 |
| WKN: | A3DSV0 |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX |
| LEI Code: | 3912003NCTLO6YHA9V48 |
| EQS News ID: | 2413024 |
| End of News | EQS News Service |
|
|
2413024 09.10.2026 CET/CEST
Bio-Gate AG reports first half results for 2026
|
Bio-Gate AG / Key word(s): Half Year Results Bio-Gate AG reports first half results for 2026 09.10.2026 / 15:55 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Bio-Gate AG Reports First-Half Results for 2026
Nuremberg/Bremen, October 9, 2026 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of proprietary antimicrobial technologies for human and veterinary medicine, generated consolidated revenue of 2.8 million euros in the first half of 2026 (as of June 30), a decline of just under 18 percent compared to the same period last year. Changes in the product portfolio and organizational restructuring—particularly in the derma-cosmetics and wound care business segments—led to significantly lower order volumes from two major customers for human and animal care products, respectively. The medical technology segment, which includes implant coatings, performed in line with expectations. However, revenue growth was weaker due to timing shifts related to specific dates in the completion of milestones. This was caused by delayed partial deliveries from a project partner. By contrast, the Veterinary and Measurement Services business segments increased their revenue contributions.
At the half-year mark, Bio-Gate reported a loss of 814 TEUR at the EBITDA level (previous year: -723 TEUR) and a loss of 927 TEUR at the EBIT level (previous year: -840 TEUR). As a result, the losses—relative to the decline in revenue—were significantly lower due to positive effects from cost-saving and efficiency measures already implemented.
The Executive Board is confident that the decline in revenue will be only a temporary phenomenon. Revenue is expected to return to 2025 levels as early as 2027. Growth momentum is expected to come, for example, from a new Bio-Gate medical device for scar treatment developed for a dermocosmetics customer. Preparations for the market launch are already underway. In addition, Bio-Gate is achieving significant cost savings through the reorganization of its corporate structures and processes along the value chain, thereby strengthening its profitability.
2026 Full-Year Forecast Revised For the full year 2026, the Executive Board expects consolidated revenue to range between 6.0 and 6.9 million euros (previous forecast from May 2026: ±7% of the prior-year level, i.e., approximately 6.9 to 7.9 million euros; previous year’s consolidated revenue: 7.4 million euros). EBITDA is expected to range between -0.9 and -1.1 million euros, which—despite the lower revenue—is at or slightly below the previous year’s level (-0.9 million euros), as cost savings will offset part of the impact of the revenue decline. Management anticipates EBIT of between -1.1 and -1.5 million euros (previous year: -1.1 million euros).
Note Bio-Gate AG’s consolidated semiannual report as of June 30, 2026, is available for download at https://www.bio-gate.de/unternehmen/ under Investor Relations/Financial Reports.
Financial Calendar 2026 November 24 Equity Forum, Frankfurt
Contacts Bio-Gate AG Neumeyerstr. 28-34 90411 Nuremberg Germany www.bio-gate.de
North America Karl Richter RFH BioTek Inc. Tel: 416-407-6120 rfh@rfhBioTek.com Toronto, Canada
Europe Falk von Kriegsheim rikutis consulting fvk@rikutis.de presse@bio-gate.de Tel. +49 (0) 911 477523-222 Mobil +49 (0)172 9837109
About Bio-Gate AG The medical technology company Bio-Gate AG develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coating and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value-adding chain, from development to approval to production. For more information, please visit www.bio-gate.de.
Disclaimer This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.
09.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Bio-Gate AG |
| Neumeyerstr. 28-34 | |
| 90411 Nürnberg | |
| Germany | |
| Phone: | +49 (0) 911 / 47 75 23 – 100 |
| Fax: | +49 (0) 911 / 47 75 23 – 101 |
| E-mail: | marc.lloret-grau@bio-gate.de |
| Internet: | www.bio-gate.de |
| ISIN: | DE000BGAG0J3 |
| WKN: | BGAG0J |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hanover, Munich (m:access), Stuttgart, Tradegate BSX |
| LEI Code: | 391200G5LKTIOTZOXP90 |
| EQS News ID: | 2413462 |
| End of News | EQS News Service |
|
|
2413462 09.10.2026 CET/CEST
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
|
ReproNovo SA / Key word(s): Personnel REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD 20.03.2026 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD Biopharma executive with more than 35 years of leadership across C-suite and board roles Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors. Mark Altmeyer brings more than 35 years of experience as a biopharma executive and board leader across large pharma and high-growth biotech companies focusing on multiple therapeutic areas. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings. Altmeyer is recognized for fostering high-performing teams, aligning investors and management around clear value-creation priorities. “Mark is distinguished by a rare blend of board-level leadership and operational excellence covering the full biopharma lifecycle, combining entrepreneurial drive with disciplined governance and a strategic, stakeholder-oriented mindset,” said Jean Marie Duvall, Chief Executive Officer and Co-Founder of ReproNovo. “He has successfully guided companies through critical development and strategic inflection points, capabilities that will be highly valuable as we globally advance RPN-001 and RPN-002 across four indications in fertility and women’s health.” Most recently, Altmeyer served as Founder and CEO of Arvelle Therapeutics, where he led the company’s transatlantic build-out, secured $200 million in financing and successfully completed a $1 billion acquisition by Angelini Pharma within two years. His earlier roles include CCO at Axovant, as well as senior commercial and general management positions at Bristol Myers Squibb and Otsuka. At Otsuka, he led the launch and expansion of Abilify to become the top selling pharmaceutical product in the U.S. in 2013, increasing revenue to over $7 billion. Across Altmeyer’s career, his leadership has spanned multiple therapeutic areas and business models, from primary care and specialty pharma to rare disease and hospital-driven markets. In addition to his executive experience, Altmeyer adds extensive board-level leadership across the biotech lifecycle, from early-stage development through late-stage growth and exit. He currently serves as Chairman of AM-Pharma and Calluna Pharma and holds non-executive or independent director roles at several public and private life sciences companies. From 2016 to 2018, Altmeyer served as an Independent Director at Myovant Sciences, which was subsequently acquired by Sumitomo Pharma in a transaction valued at approximately $3 billion. Commenting on his appointment, Mark Altmeyer said: “ReproNovo is addressing critical therapeutic gaps in areas that have seen limited innovation, despite these being really large markets. I look forward to working with the Board and management team to maximize these highly differentiated products, create value and ultimately bring these products to patients.” ABOUT REPRONOVO: CONTACT INFORMATION: MEDIA CONTACT: Mark Altmeyer
20.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2294576 20.03.2026 CET/CEST
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
|
Galimedix, Inc. / Key word(s): Conference Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026 20.03.2026 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, presented preclinical data showcasing the improved pharmacokinetic (PK) profile of a next-generation amyloid-beta (Aβ) aggregation modulator for Alzheimer’s disease. The poster, entitled, “New oral prodrug of the Aβ aggregation modulator GAL-201 shows significantly improved pharmacokinetic profile”, was presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2026: advances in science and therapy), being held in Copenhagen, Denmark, March 17-21, 2026. “The data presented at AD/PD™ 2026 demonstrate the rapid absorption and significantly higher peak plasma concentrations of this new prodrug compared to the parent compound,” said Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix. “These characteristics make this prodrug a promising new oral Aβ-targeting development candidate that could offer enhanced efficacy and patient-friendly dosing for the long-term treatment of Alzheimer’s disease.” Prodrug demonstrates rapid and complete absorption, enabling reduced oral doses, important for long-term administration This superior PK profile enables significantly reduced oral doses, which is particularly important given the need for long-term administration for patients with Alzheimer’s disease. The poster can be accessed here: AD/PD 2026: Galimedix Poster About Galimedix Therapeutics, Inc. Contact Media inquiries:
20.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2294486 20.03.2026 CET/CEST
Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
|
Newron Pharmaceuticals S.p.A. / Key word(s): Conference Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) 20.03.2026 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) Presentations explore the role of glutamatergic modulation in treatment-resistant schizophrenia (TRS) across preclinical and clinical research Milan, Italy, and Morristown, NJ, USA, March 20, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy. Workshop
Posters
Friday, March 27, 2026
Saturday, March 28, 2026
About ENIGMA-TRS About evenamide About treatment-resistant schizophrenia (TRS) About Newron Pharmaceuticals For more information, please contact: Newron UK/Europe Switzerland Germany/Europe USA
20.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Newron Pharmaceuticals S.p.A. |
| via Antonio Meucci 3 | |
| 20091 Bresso | |
| Italy | |
| Phone: | +39 02 610 3461 |
| Fax: | +39 02 610 34654 |
| E-mail: | pr@newron.com |
| Internet: | www.newron.com |
| ISIN: | IT0004147952 |
| WKN: | A0LF18 |
| Listed: | Regulated Unofficial Market in Dusseldorf (Primärmarkt); SIX |
| EQS News ID: | 2294830 |
| End of News | EQS News Service |
|
|
2294830 20.03.2026 CET/CEST
Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
|
Marinomed Biotech AG / Key word(s): Capital Increase Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million 19-March-2026 / 16:14 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad hoc announcement Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
Korneuburg, Austria, March 19, 2026 The Executive Board of Marinomed Biotech AG (“Company”) resolved today, with the approval of the Supervisory Board, to carry out a capital increase against cash contributions—while preserving the subscription rights of existing shareholders—by partially utilizing the authorized capital provided for in Section 5(6) of the Articles of Association, in order to meet short-term capital requirements, and to increase the share capital from the current EUR 1,839,940 by up to EUR 459,985 through the issuance of up to 459,985 new no-par value bearer shares (“New Shares”) with a notional proportionate amount of the share capital of EUR 1.00 per share to up to EUR 2,299,925 (the “Capital Increase”). Existing shareholders of the Company (“Existing Shareholders”) will be granted subscription rights (“Subscription Rights”) on a 4:1 basis, i.e., for every four existing shares, one New Share may be subscribed for at a subscription price of EUR 14.00 per New Share (“Subscription Price”). The goal of the transaction is to generate gross proceeds of at least EUR 2 million. Because the Company has not yet received sufficient payments from the transfer of the Carragelose business to Unither Pharmaceuticals (“Unither”), the Company has a short-term capital requirement to cover its anticipated liquidity needs of approximately EUR 2 million until mid of the fiscal year 2026. The net proceeds from the capital increase are therefore to be used to fulfill the restructuring plan and close the financing gap. The Company will make use of the prospectus exemptions provided for in Article 1(4)(db) and Article 1(5)(ba) of Regulation (EU) 2017/1129 (“Prospectus Regulation”), as amended, in connection with the offering of the New Shares and the admission of the New Shares to trading on the Vienna Stock Exchange. The document required for this purpose pursuant to Annex IX of the Prospectus Regulation will be filed in electronic form with the Financial Market Authority (FMA), as the competent authority of the home Member State, prior to the commencement of the public offering and will be made available to the public at the same time as it is filed with the FMA via the website www.marinomed.com. The record date for the entitlement of existing shareholders to subscribe for New Shares is March 25, 2026, at 11:59 p.m. CEST (“Record Date”). The subscription period is scheduled to begin on March 26, 2026 9:00 a.m. Central European Time and is expected to end on April 9, 2026 5:40 p.m. Central European Time, although the subscription period may be extended at any time. The subscription rights will not be tradable on the Vienna Stock Exchange. Any New Shares not subscribed for through the exercise of subscription rights in connection with the subscription offer (“Rump Shares”) will be offered following the subscription offer as part of a prospectus-exempt private placement (“Rump Placement”) to eligible institutional investors and selected non-institutional investors within the European Economic Area at the Subscription Price. A binding commitment has been received from an institutional investor who, as of today, does not yet hold any shares in the Company, to subscribe for and acquire New Shares in the total amount of EUR 1 million at the Subscription Price as part of the Rump Placement. This announcement is made in accordance with Article 17 of the Market Abuse Regulation (EU) No. 596/2014. Disclaimer: The New Shares and Subscription Rights have not been and will not be registered under any foreign securities laws—in particular under the U.S. Securities Act of 1933, as amended (“Securities Act”) – with foreign securities authorities and may not be offered or sold, in particular in the United States of America (“U.S.”), without registration or an exemption from the registration requirements under the Securities Act. This announcement is not intended for distribution in the U.S. or within the U.S. and may not be distributed or forwarded to publications with general circulation in the U.S. Foreign shareholders may be subject to restrictions on the exercise of their subscription rights. Foreign shareholders are therefore urged to inform themselves of the restrictions applicable to them regarding the exercise of subscription rights. This announcement is neither an offer to sell nor a solicitation of an offer to subscribe for or purchase securities in countries where such an offer or solicitation is legally prohibited. +++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. End of Inside Information 19-March-2026 CET/CEST News transmitted by EQS Group |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2294718 |
| End of Announcement | EQS News Service |
|
|
2294718 19-March-2026 CET/CEST
MEDICLIN invites you to the 2026 virtual press conference on the financial statements for the year 2025
|
MEDICLIN AG / Key word(s): Conference/Miscellaneous MEDICLIN invites you to the 2026 virtual press conference on the financial statements for the year 2025 19.03.2026 / 15:15 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Press conference The Management Board of MEDICLIN will report on the 2025 financial year, current developments at MEDICLIN and the outlook for 2026 in a webcast. Following the presentation by the Management Board, you will have the opportunity to ask questions. The presentation will be held in German. To participate in the press conference, please register at the following link (German only): MEDICLIN virtual press conference on the financial statements for the year 2023 You will then receive the link to the webcast and the dial-in details for the telephone conference. Please note that whilst the webcast provides an audio feed via your internet browser, you will need to dial in by telephone to actively participate and ask questions. Please dial in 10 minutes before the start of the event. The replay of the webcast (without the Q&A session) will be available on the MEDICLIN website soon after the press conference. We look forward to your participation. CONTACT MEDICLIN Aktiengesellschaft is one of Germany’s leading healthcare providers, with a clear focus on medical rehabilitation. MEDICLIN operates 31 clinics, six long-term care facilities, and ten medical care centers across Germany. MEDICLIN employs approximately 9,900 people. Through a strong network, MEDICLIN offers integrated care ranging from the initial doctor’s visit through surgery and subsequent rehabilitation to outpatient follow-up care. Medical and therapeutic staff, as well as nursing staff, work together in close coordination. MEDICLIN tailors the care and support provided to people in need of care to their individual needs and personal requirements. MEDICLIN is a company of the ASKLEPIOS Group.www.mediclin.de
19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | MEDICLIN AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2294652 |
| End of News | EQS News Service |
|
|
2294652 19.03.2026 CET/CEST
Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard
|
Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard 19.03.2026 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard
Martinsried (Munich), Germany, March 19, 2026 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the establishment of an Advisory Board to support the Company’s growth trajectory. Financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard have been appointed members of the Board. The Advisory Board aims to provide strategic guidance as well as financial and industry expertise to support sustainable business growth as Secarna strives to fulfill on its mission to transform untreatable medical conditions into treatable ones by leveraging its AI-empowered OligoCreator® platform to identify and characterize oligonucleotide therapeutics and bringing its lead compound SECN-15 to clinical proof of concept (POC). “We are delighted to welcome such experienced industry leaders to our Advisory Board at this pivotal stage of Secarna’s development,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “We look forward to building on their industry perspectives and combined experience to help drive our long-term growth objectives.” Jens Holstein, former CFO of BioNTech SE, commented: “I’m excited to join Secarna’s Advisory Board and support the Company as it continues its journey as a leading developer of oligonucleotide therapeutics. I look forward to contributing my financial and corporate strategy expertise in the life sciences, biotech and pharma environment to help guide sustainable growth and long-term value creation.” Richard Mark Engelhard, representing shareholder Engelhard Arzneimittel GmbH & Co KG, stated: “Secarna’s recent development demonstrates the strength of its AI-empowered platform as well as it’s growing proprietary pipeline with SECN-15 as novel, potential best-in-class oligonucleotide in the field of oncology. I am pleased to join the Advisory Board and further support the management team as the Company continues to scale and execute on a compelling long-term growth and value-creation trajectory. Having supported Secarna for many years as a shareholder, I’m excited to now contribute in this expanded role.” Richard Mark Engelhard is General Manager of Engelhard Arzneimittel GmbH & Co. KG, one of the leading brand-name manufacturers in the OTC medicines segment. Jens Holstein has over 30 years of leadership experience in the life sciences and biopharmaceutical sector. In 2021 he joined BioNTech SE as CFO and retired from this position mid of 2025. BioNTech is well-known for its pioneering work in immunotherapies and for its mRNA vaccines, including its COVID-19 vaccine Comirnaty®. At BioNTech, he led the financial strategy that supported the company’s growth into a global, fully integrated immunotherapy leader. Prior to this position, he served for almost 10 years as CFO of MorphoSys AG. He was instrumental in transforming the company into a fully integrated biopharmaceutical player. MorphoSys has been listed in Germany (MDAX) and the US (NASDAQ). He also held executive roles within the Fresenius SE Group, including Regional CFO for EMEA and Regional CFO of Fresenius Kabi Asia Pacific Ltd. He also served as Managing Director at Fresenius ProServe GmbH and CFO of its subsidiary Wittgensteiner Kliniken AG. He is currently a non-executive member of the Board of Directors of the US-listed diagnostic company Veracyte Inc. and serves as Chairman of the audit committee. He holds a degree in Business Administration (Dipl. Kfm) from the University of Münster. About Secarna Pharmaceuticals Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities. With the Company’s proprietary AI-empowered OligoCreator® platform, which includes multiple delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By delivering these novel therapeutics to the cells, organs, or tissues where they are needed, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Secarna’s unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine. www.secarna.com
Contact Secarna Pharmaceuticals GmbH & Co. KG For media inquiries MC Services AG Email: secarna@mc-services.eu
19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2293244 19.03.2026 CET/CEST
Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
|
Pentixapharm Holding AG / Key word(s): Annual Report Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026 (news with additional features) 19.03.2026 / 10:14 CET/CEST The issuer is solely responsible for the content of this announcement. Pentixapharm Holding AG – FY 2025 Review & Management Outlook
Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026.
To participate in the conference call, please register via the following link: About Pentixapharm Holding AG Additional features: File: JA 2025 Einladung Earnings Call_PTX_ENG
19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2294404 |
| End of News | EQS News Service |
|
|
2294404 19.03.2026 CET/CEST